E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Same-day hysterectomy |
Hysterktomi |
|
E.1.1.1 | Medical condition in easily understood language |
Removal of the uterus |
Fjernelse af livmoderen |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10023692 |
E.1.2 | Term | Laparoscopically assisted hysterectomy |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is to investigate the effect of a single dose of intravenous intraoperative methadone on postoperative opioid consumption, pain and side effects in patients scheduled for hysterectomy for benign indications. A single dose of intravenous intraoperative morphine will be used as an active comparator. |
Formålet med studiet er at undersøge effekten af en enkelt dosis af iv metadon givet intraoperativt på effekten af det postoperative opioid behov, smerte og bivirkninger hos patienter som skal have foretaget en hysterktomi pga benign indikation. En enkelt dosis af iv intraoperativt morfin anvendes som aktivt samligning. |
|
E.2.2 | Secondary objectives of the trial |
• Pain intensity (NRS, 0-10) at rest and coughing at 0.5, 1, 3, 6, 24, 48 and 72 hours after extubation • Patient satisfaction (NRS, 0-10) with pain management at 3 and 24 hours after extubation • Nausea and/or vomiting (PONV) on a 4 point Likert scale (none/mild/moderate/severe) at 6, 24 and 72 hours • Time from arrival to readiness for discharge from PACU and hospital (hours and minutes). • Level of sedation at observation at the PACU (Ramsay Sedation Scale [20] at 0.5, 1 and 3 hours after extubation) • Any adverse events during observation at the PACU: o Hypoventilation (respiratory rate < 10/minutes) o Hypoxemia (peripheral oxygen saturation < 90%)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All patients scheduled for elective laparoscopic hysterectomy for benign indications are screened for inclusion |
|
E.4 | Principal exclusion criteria |
Patients with one of the following criteria are excluded: • American Society of Anaesthesiologists (ASA) physical status IV or V [21]: • Prolonged QT-interval assessed by electrocardiogram (> 440 milliseconds). • Existing treatment with medications prolonging the QT-interval (see appendix for details) • Hysterectomy due to malignancy or acute bleeding disorders • Allergy to study drugs • Preoperative daily use of opioids or • Inability to provide informed consent
Secondary exclusion criteria: • Intraoperative conversion to open surgery.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcomes: • Opioid consumption at 24 hours (mean cumulative opioid consumption) • Opioid consumption at 6 hours after extubation (mean cumulative opioid consumption)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 and 24 hours after extubation. |
|
E.5.2 | Secondary end point(s) |
Secondary outcomes: • Pain intensity (NRS, 0-10) at rest and coughing at 0.5, 1, 3, 6, 24, 48 and 72 hours after extubation • Patient satisfaction (NRS, 0-10) with pain management at 3 and 24 hours after extubation • Nausea and/or vomiting (PONV) on a 4 point Likert scale (none/mild/moderate/severe) at 6, 24 and 72 hours • Time from arrival to readiness for discharge from PACU and hospital (hours and minutes). • Level of sedation at observation at the PACU (Ramsay Sedation Scale [20] at 0.5, 1 and 3 hours after extubation) • Any adverse events during observation at the PACU: o Hypoventilation (respiratory rate < 10/minutes) o Hypoxemia (peripheral oxygen saturation < 90%) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
0.5, 1, 3, 6, 24, 48 and 72 hours after extubation and 4 months after surgery. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit, last patient. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |